INTRODUCTION

Haemophagocytic lymphohistiocytosis (HLH) denotes a potentially lethal, systemic hyperinflammatory syndrome. HLH has been linked to intracellular infections ranging from herpesviruses and influenza to visceral leishmaniasis that elicit strong T cell-mediated immune responses. As such, HLH can be viewed as an exaggerated immune response that in certain settings can be successfully treated with radical immunosuppressive regimens rather than treatments targeting the infection. T cell-mediated immune responses also contribute to control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, but patients very seldom fulfil HLH criteria. HLH has also associated with malignancies and autoinflammatory syndromes. In addition, iatrogenic HLH

Abstract

Haemophagocytic lymphohistiocytosis (HLH) represents a life-threatening hyperinflammatory syndrome. Familial studies have established autosomal and X-linked recessive causes of HLH, highlighting a pivotal role for lymphocyte cytotoxicity in the control of certain virus infections and immunoregulation. Recently, a more complex etiological framework has emerged, linking HLH predisposition to variants in genes required for metabolism or immunity to intracellular pathogens. We review genetic predisposition to HLH and discuss how molecular insights have provided fundamental knowledge of the immune system as well as detailed pathophysiological understanding of hyperinflammatory diseases, highlighting new treatment strategies.

KEYWORDS

haemophagocytic lymphohistiocytosis, hyperinflammation, immune dysregulation, inborn errors of immunity, macrophage activation syndrome

1 | INTRODUCTION

Haemophagocytic lymphohistiocytosis (HLH) denotes a potentially lethal, systemic hyperinflammatory syndrome. HLH has been linked to intracellular infections ranging from herpesviruses and influenza to visceral leishmaniasis that elicit strong T cell-mediated immune responses. As such, HLH can be viewed as an exaggerated immune response that in certain settings can be successfully treated with radical immunosuppressive regimens rather than treatments targeting the infection. T cell-mediated immune responses also contribute to control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, but patients very seldom fulfil HLH criteria. HLH has also associated with malignancies and autoinflammatory syndromes. In addition, iatrogenic HLH
has been associated with chimeric antigen receptor T-cell therapies, gene therapies, antibody therapies including rituximab and immune checkpoint inhibitors, as well as allogeneic stem-cell transplantation. Here, we provide a historical perspective on studies that have uncovered genetic factors that predispose to the development of HLH. Importantly, these studies have unravelled how several different immunological pathways can contribute to disease, thereby highlighting new therapeutic targets.

2 | HISTORICAL BACKGROUND

Reports of adults with a rare and invariably fatal condition characterised by relapsing fever, progressive erythropenia, neutropenia, a highly reactive marrow and hepatosplenomegaly are considered the first descriptions in the medical literature of what is currently termed HLH.1,2 In 1952, Farquhar and Claireaux described two infant siblings that were presented with familial so-called ‘haemophagocytic reticulosis’ with a fatal outcome, providing the first indication of a strong genetic contribution to such life-threatening hyperinflammatory syndromes.3 In a seminal study, Fauci and colleagues found that NK cell cytotoxicity was severely impaired in patients with autosomal recessive Chediak-Higashi syndrome (CHS),4 which is characterised by defective pigmentation, abnormal leukocyte granulation and increased susceptibility to infections. Affected children, as Filipovich and colleagues observed, develop fatal HLH or alternatively lymphomas in childhood or adolescence.4,5 An animal model of CHS, the beige mouse, similarly displayed defective NK cell cytotoxicity.6 In the mid-1980s, research constellations including Griscelli, Arico and Janka reported defective NK cell cytotoxicity in children with suspected familial HLH and normal pigmentation.6–8 In most of these patients, NK cell cytotoxicity remained persistently impaired irrespective of splenectomy, corticosteroids, chemotherapy or whether their cells were investigated during hyperinflammation or in remission. However, in a few patients, NK cell activity was restored following treatment.9 Furthermore, in a key study Henter and colleagues analysed serum from familial HLH patients revealing highly elevated interferon (IFN)-γ, tumour necrosis factor (TNF) and soluble CD8 levels in the patients.9 These findings led to the classification of familial HLH as a disease of systemic hypercytokinaemia and suggested an important role for IFN-γ and TNF as well as CD8+ T cells in the pathogenesis, in line with histological observations of activated macrophages and CD8+ T cells infiltrations in multiple tissues of HLH patients.10

Spurred by a wealth of clinical observations and laboratory findings, Henter and colleagues led initial consensus efforts to define HLH, with the first Histiocyte Society diagnostic guidelines which were published in 1991.11 These guidelines stipulated unremitting fever, splenomegaly, bicytopenia, hypertriglycerideremia/hypofibrinogenemia and haemophagocytosis as requirements for a diagnosis of HLH. At the time, it was recognised that HLH could present as a primary early-onset, autosomal recessive condition or develop secondary to stimuli that induced a strong activation of the immune system, including infections (particularly by viruses), malignancies and prolonged intravenous administration of soluble lipids.11 In rheumatic diseases, particularly systemic onset juvenile rheumatoid arthritis, the term macrophage activation syndrome (MAS) was increasingly used to describe a constellation of symptoms similar to HLH that also could be treated by immunosuppressive drugs.12,13 These first diagnostic guidelines increased awareness, facilitated systematic studies and provided new insights to HLH. Imashuku and colleagues identified high serum ferritin as a hallmark of histiocytosis associated with viral infections as well as malignancy.14 Soluble CD25 was later described as elevated in HLH patients and recognised as a predictor of poor outcome.15 Furthermore, it had earlier been noted that haemophagocytosis was not always evident or could be missed in the diagnostic evaluation.10 According to these insights, the Histiocyte Society diagnostic guidelines for HLH were modified to include hyperferritinaemia, elevated serum CD25 and impaired NK cell cytotoxicity, with a diagnosis based upon fulfilment of five out of a total of eight criteria.16 These clinical, laboratory and histological criteria have provided a crucial framework to dissect the genetic underpinnings of HLH.

Here, we discuss how these groundbreaking initiatives have led to a rich understanding of the genetic susceptibility as well as the molecular and cellular pathophysiology of HLH. We highlight advances as well as unanswered questions. In addition, we discuss how current knowledge of a spectrum of HLH-related disorders can aid efforts to provide precision medicine for individuals suffering from diverse hyperinflammatory disorders.

3 | GENETIC DISSECTION OF FAMILIAL HLH

3.1 | Initial associations of haemophagocytic lymphohistiocytosis to defective lymphocyte cytotoxicity

Genetic linkage studies were instrumental in identifying the first genes known to cause HLH, benefiting from advances in molecular cloning and sequencing techniques as well as human genome
mapping efforts. In 1996, two groups identified a variant in Lyst as causative of the mouse beige phenotype by screening of yeast artificial chromosome libraries. Deleterious LYST variants were also uncovered in a CHS patient. At the time, it was known that CHS arises from a secretory defect that prevents the exocytosis of perforin-containing cytotoxic granules, a form of specialised secretory lysosome specifically expressed in cytotoxic T cells and NK cells. LYST is also required for biogenesis of melanosomes in melanocytes, explaining hypopigmentation in CHS. Perforin is specifically expressed by cytotoxic T cells and NK cells and, together with Fas, represents the major pathway for lymphocyte-mediated target cell killing. Upon exocytosis, perforin forms pores in target cell membranes that facilitate entry of pro-apoptotic granzymes, which also are stored in cytotoxic granules. In 1998, through linkage analyses, variants in SH2D1A were identified as a cause of X-linked lymphoproliferative disease type 1 (XLP1), which is characterised by fulminant, life-threatening Epstein-Barr virus (EBV) infections fulfilling HLH criteria, dysgammaglobulinaemia, as well as EBV-related lymphoproliferative disorders, or lymphoma. SH2D1A encodes SAP, a signalling protein that binds the phosphorylated cytoplasmic tail of a variety of SLAM family receptors that are widely expressed on hematopoietic cells, thereby preventing recruitment of phosphatases that otherwise convey signals that inhibit cell-cell interactions. These early discoveries thus implicated impaired perforin-mediated cytotoxicity and dysregulated lymphocyte interactions in susceptibility to severe EBV infections and development of HLH. They paved the way for a detailed molecular understanding of genetic predisposition to HLH.

### 3.2 Identification of autosomal recessive genes causative of familial HLH

In 1999, performing linkage analyses of consanguineous families, Kumar and colleagues uncovered autosomal recessive variants in PRF1, encoding perforin, as a cause of familial HLH. Notably, they concluded that perforin-based effector systems are involved not only in the killing of abnormal cells but also in the down-regulation of cellular immune activation. Perforin deficiency is termed familial HLH type 2 (FHL2). Shortly thereafter, de Saint Basile and colleagues showed that variants in RAB27A cause Griscelli syndrome type 2 (GS2), an autosomal recessive disorder of pigmentation also characterised by development of HLH. RAB27A encodes a small GTP-binding protein preferentially expressed by melanocytes and hematopoietic cells which is required for cytotoxic granule exocytosis by lymphocytes. In subsequent linkage studies of other familial HLH pedigrees, autosomal recessive variants in UNC13D, STX11 and STXBP2 were identified as causative of FHL3-5. These genes encode the cytosolic proteins Munc13-4, syntaxin-11 and Munc18-2, respectively. They display high sequence homology to the presynaptic neuronal proteins that regulate SNARE-complex mediated neurotransmitter release but are instead expressed in lymphocytes and other hematopoietic cell lineages. Munc18-2 is also expressed in epithelial cells of the gut, potentially explaining the gastrointestinal manifestations that are a particular feature of Munc18-2 deficient patients. Importantly, studies of lymphocytes from patients with biallelic nonsense variants in these genes have established that their protein products are required for lymphocyte cytotoxic granule exocytosis, explaining why such variants give rise to syndromes that clinically phenocopy perforin-deficiency (Figure 1). Retrospective analyses have demonstrated that patients with biallelic nonsense variants in PRF1 or UNC13D invariably present with HLH within their two first years of life. Nonsense variants in STXBP2, RAB27A and in particular STX11 may present later in childhood, which can be explained by the fact that cytokine stimulation of cytotoxic lymphocytes can restore exocytosis by syntaxin-11 deficient cells.

Altogether, a number of genetic studies determined that defective lymphocyte cytotoxicity is a frequent cause of familial HLH, highlighting how lymphocyte cytotoxicity is crucial for maintenance of immune homeostasis. They also illustrated how rare human diseases, characterised by genetic variants and frequently triggered by infectious agents, can provide molecular and pathophysiological insights that are not easily uncovered in animal model systems.

### 3.3 Non-coding variants as a cause of familial HLH

The incidence of autosomal recessive familial HLH in infancy and childhood has been estimated as 1/50 000 live-births, which is, for example comparable to that of severe combined immunodeficiency. Great advances in sequencing technologies have facilitated a molecular diagnosis in a large number of patients and unravelled many new primary immunodeficiency diseases. Nonetheless, high-throughput sequencing efforts currently focus on analyses of the coding regions of genes and may fail to identify non-coding disease-causing variants in a majority of patients with suspected Mendelian inheritance. Meticulous clinical, functional and genetic analyses of patients with early-onset HLH and defective lymphocyte cytotoxicity have revealed that non-coding variants can explain more than 50% of early-onset HLH cases, at least in some geographical regions. These studies have revealed a lymphocyte-specific intrinsic enhancer and alternative transcriptional start site of UNC13D controlled by ETS family transcription factor binding. In the same intron, another variant impairing NFκB transcription factor binding has been associated with reduced UNC13D transcription in a patient diagnosed with recurrent MAS. Moreover, deletions of the RAB27A promoter have been reported in GS2, in some cases deleting a lymphocyte-specific promoter that thereby impairs lymphocyte cytotoxicity without affecting the pigmentation of melanocytes.

Future efforts promise to unravel many more disease-causing variants in non-coding gene regulatory elements, which can be facilitated by analyses of evolutionary conservation and knowledge of non-coding elements that may regulate HLH-associated genes. Importantly, sensitive functional assays and determination of protein
expression complement to high-throughput genetic analyses, as they can direct analyses for as well as determine the functional impact of rare, non-coding variants.51–53 Such efforts can hopefully substantially increase the proportion of patients that obtain a molecular diagnosis.

3.4 Molecular pathophysiology of familial HLH, new genetic susceptibilities and future prospects

The genetic dissection of familial HLH has provided a platform for molecular understanding of lymphocyte exocytosis. At transient immune synapses between cytotoxic lymphocyte and target cells, syntaxin-11 is bound by Munc18-2. Upon activating receptor signals, syntaxin-11 is recruited to the synapse through the directed fusion of recycling endosomes with the plasma membrane.54 Signals from activating receptors also recruit Munc13-4 to cytotoxic granules, where it interacts with Rab27a and promotes docking of the cytotoxic granules at the immune synapse through binding of RhoG, a protein that can provide membrane anchoring through covalent lipid modifications. Stx11 interacts with other SNARE proteins, mostly likely plasma membrane SNAP-23 and a vesicular SNARE, to drive the final step of cytotoxic granule fusion and exocytosis that mediates the release of perforin and granzymes into the immune synapse. Perforin multimers can form pores in the target cell membrane that facilitate entry of granzymes into the cytosol of the target cell where they promote apoptosis. Proteins encoded by genes associated with primary HLH are highlighted in bold.
HLH have established a requirement for syntaxin-11 in lymphocyte exocytosis, the SNARE protein complex partners have not been unequivocally defined. For example, it is not clear whether VAMP2, VAMP7, VAMP8 or another R-SNARE on cytotoxic granules mediates fusion and why there may be differences between species.\(^6^3\)\(^-^6^5\)

Further mechanistic studies of lymphocyte cytotoxicity in cells from patients as well as in experimental systems can provide important insights into HLH susceptibility. It is possible that genetic variants in other more ubiquitously expressed proteins involved in SNARE-mediated lymphocyte exocytosis also contribute to HLH predisposition, accounting for additional patients.

4 | OTHER GENETIC CONTRIBUTIONS TO HLH SUSCEPTIBILITY

In 2006, Latour and colleagues identified hemizygous loss of function variants in XIAP as the cause of XLP2, with patients often presenting with EBV infection and 92% (11/12) of patients fulfilling HLH criteria.\(^6^6\) A more comprehensive review of patients with XIAP deficiency reported that 54% of patients manifest with HLH during the course of disease.\(^6^7\) In contrast to XLP1, no increased risk of lymphoma has been reported. Rather, patients may present clinically with splenomegaly or inflammatory bowel disease (IBD).\(^6^7\)

XIAP is a ubiquitously expressed inhibitor of apoptosis but also regulates inflammasome activity.\(^6^8\) In this context, de novo activating NLRC4 variants have been shown to cause severe, early-onset HLH.\(^6^9\) Dysregulation of the actin cytoskeleton has also been linked to inflammasome activation and HLH predisposition. Patients with de novo variants in CDC42, encoding Cdc42, a protein which is a small Rho family GTPase that regulates actin dynamics, have been described with HLH in the absence of infections.\(^7^0\) Similar to patients with NLRC4-related autoinflammatory disease, interleukin 18 (IL-18) was elevated in patients with de novo CDC42 mutations. Thus, IL-18 may co-stimulate IFN-γ production for development of HLH in a mechanism distinct from antigen-driven activation in patients with mutations in genes required for lymphocyte cytotoxicity. Disease-associated variants in other genes are further substantiating the links between actin dysregulation, inflammasome activation and HLH.

An association between EBV and genetic susceptibility to HLH was highlighted with the identification of variants in SH2D1A as a cause of XLP1.\(^2^2\)\(^-^2^4\) HLH is the presenting feature of approximately 40% of XLP1 patients.\(^7^1\) High-throughput sequencing efforts have associated autosomal recessive variants in CD27, CD70, CORO1A, CTPS1, ITK, RASGRP1, TNFSFR9 (encoding CD137/4-1BB) and X-linked variants in MAGT1, with primary immunodeficiency diseases (PID) characterised by life-threatening EBV infections.\(^7^2,^7^3\) Several of these PIDs have been associated with development of HLH. Furthermore, while studies of familial HLH patients and perforin-deficient animal models have indicated a critical role for CD8\(^+\) T cell-mediated target cell killing and IFN-γ in the pathogenesis of familial HLH,\(^7^4\) a number of associations between HLH and congenital diseases other than defects in lymphocyte cytotoxicity provide a more complex pathophysiological picture. HLH has been reported in HLH patients virtually lacking T cells.\(^7^5\) Moreover, reports of patients with autosomal recessive variants in IFNGR1, IFNGR2 and STAT1 indicate that HLH can develop upon severe infections yet in the absence of IFN-γ signaling.\(^7^6-^7^8\) These PID patients illustrate how clinical features of HLH can develop without CD8\(^+\) T cell-mediated target cell killing or IFN-γ.

More than 30 years ago, it was recognised that HLH may occur in patients with prolonged intravenous administration of soluble lipids.\(^1^1\) Since then, HLH has been associated with a number of inborn errors of metabolism (IEM), including Wolman disease, Niemann-Pick disease, Gaucher disease, lysinuric protein intolerance, multiple sulfatase deficiency, galactosaemia, Pearson syndrome, galactosialidosis, propionic acidemia, methylmalonic acidemia, biotinidase deficiency, cobalamin C deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and disorders of glycosylation (COG6 deficiency).\(^7^9\) These genes typically encode ubiquitously expressed proteins. Thus, clinical presentation may involve different organs and tissues, directly or indirectly affecting the immune system. Cytopenias and organomegaly are common pathophysiological features of IEMs. IEM patients that fulfil HLH-2004 criteria generally differ from other forms of HLH by being more commonly associated with a failure to thrive, vomiting, muscular hypotonia and acidosis as well as a lack of fever.\(^8^0\)

Altogether, these findings greatly expand the spectrum of gene variants that can predispose to HLH, highlighting the importance of inflammatory pathways other than those mediated by over-activated CD8\(^+\) T cells. The involvement of the inflammasome and of several pro-inflammatory innate cytokines in HLH development provides new therapeutic targets.

5 | NEW PATHOPHYSIOLOGICAL INSIGHTS TO HLH AND NOVEL THERAPEUTICS

Current HLH criteria were created to identify patients with familial HLH in immediate need of immunosuppressive therapy. However, these criteria also include patients with pathophysiological mechanisms besides defects in lymphocyte cytotoxicity, that is impaired pathogen control, dysregulated inflammasome activation and metabolic disorders. An era of biological therapies targeting different facets of the immune system offers new possibilities for personalised treatment of treatment of HLH and related hyperinflammatory disorders.\(^8^1\)

The genetic dissection of familial HLH has enabled efforts to dissect the cellular components driving HLH pathophysiology in the context of defective lymphocyte cytotoxicity in animal gene knockout models (Figure 2). Jordan and colleagues infected Prf1\(^–/–\) mice with lymphocytic choriomeningitic virus (LCMV), providing a model that recapitulated key clinical features of familial HLH.\(^2^4\) In line with early discoveries suggesting an important CD8\(^+\) T cells as well as IFN-γ in
the pathogenesis of HLH, infection of Prf1−/− mice has demonstrated that antibodies depleting or neutralising CD8 and IFN-γ but not TNF, can ameliorate disease and reduce fatality. Based on these observations, emapalumab, an anti-IFN-γ antibody, has been tested and shown efficacious for the treatment of familial HLH. Importantly, IFN-γ independent pathways of HLH development exist, as exemplified by patients with genetic defects in the IFN-γ pathway, and Prf1−/− and Ifng−/− double knockout mice can develop HLH upon infection with LCMV. Furthermore, in a study where HLH-like disease was triggered upon murine cytomegalovirus infection of Prf1−/− or Gzma−/−Gzmb−/− mice, TNF rather than IFN-γ neutralisation ameliorated disease. IFN-γ and TNF may actually synergistically induce cell death as well as cytokine-storm-related mortality in mice. In a SARS-CoV-2 mouse model, combined neutralisation of IFN-γ or TNF was required to fully protect from lethality. Thus, the efficacy of blocking IFN-γ for broadly treating HLH needs further exploration. In mouse models, distinct viruses cause immunopathology with different dependencies on IFN-γ and TNF. These observations provide a rationale for multi-modal targeting of inflammatory cytokines in HLH and other cytokine storm-related syndromes.

The observation that HLH can develop in a lymphocyte-independent manner by macrophage activation and release of inflammatory cytokines, for example as seen in severe combined immunodeficiency patients with undetectable numbers of T cell and NK cells, or mouse models of MAS with repeated administration of TLR ligands together highlight the importance of innate immune cytokines in the pathophysiology of HLH. A promising therapy is inhibition of JAK1/2 kinases with, for example the small molecular inhibitor ruxolitinib. JAK1 and JAK2 are required for signalling by multiple cytokines, and inhibitors can thereby target IL-2 and other γ-chain-dependent, IL-6, IL-10 family, IL-12 family, as well as type I and II IFN receptors. Ruxolitinib reduces clinical manifestations of HLH-like disease in mouse models of familial HLH triggered by LCMV infection as well as MAS models with repeated TLR ligand stimulation. Moreover, ruxolitinib has shown promising results for the treatment of HLH patients.

**FIGURE 2** Schematic illustration of the pathophysiology in familial HLH caused by defective perforin-mediated lymphocyte cytotoxicity. A triggering factor such as target cell infection induces activation of macrophages and expansion of activated T lymphocytes. Cytotoxic T lymphocytes and NK cells are important for killing of infected cells as well as in the immunoregulatory down-modulation of the immune response. In patients with defective lymphocyte cytotoxicity, this immunoregulation is defective allowing excessive expansion of immune cells and secretion of pro-inflammatory cytokines that lead to hallmarks of HLH with persisting fever, splenomegaly and cytopenia.

**FIGURE 3** Diagram summarises genes that have associated with HLH and indicate to which degree mutations predispose to HLH (red—high likelihood, orange—intermediate, yellow—low likelihood). Patients with nonsense variants in genes required for lymphocyte cytotoxicity invariably present with HLH their first years of life. Patients with inborn errors of immunity may develop HLH in settings of fulminant infection with high load of pathogen associated molecular patterns. A range of metabolic disorders have been associated with development of HLH, but it remains unclear to what extent infections contribute to triggering and pathogenesis.
Thus, several different of biological therapies and small molecules hold promise for treatment of HLH. Combinations of these may be beneficial, but trials are needed to determine their efficacy in different forms of HLH. Small molecules that broadly inhibit cytokine signalling are an attractive option, as they can block multiple pathways implicated in lymphocyte as well as inflammasome-driven forms of HLH.

6 | CONCLUSION

Over the last 30 years, the Histiocyte Society’s clinical definition of HLH has been a cornerstone for defining hyperinflammatory patients with poor outcome. This definition has inspired and fuelled a large number of investigators to identify the underlying causes of HLH, uncovering a range of genetic syndromes that to a varying degree, and potentially triggered by different spectrums of infections, predispose to life-threatening disease (Figure 3). Ultimately, these investigations have provided mechanistic understanding of different pathways that can promote inflammation and immunopathology, providing fundamental understanding of the immune system and novel insights that drastically can improve the treatment of HLH patients. With an increasingly rapid turnover of genome-wide sequencing, novel biomarkers that can differentiate different categories of HLH pathogenesis, and an array of therapeutic options, precision medicine of HLH as well as related inflammatory disorders is achievable.

ACKNOWLEDGMENTS

We dedicate this review to Jan-Ingel Henter who fostered our interest in hyperinflammatory disorders. He has always enthusiastically shared his wealth of knowledge, collaborated across borders and oceans, worked tirelessly and inspired countless scientists to work together to understand and find cures to HLH.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

ORCID

Yenan T. Bryceson https://orcid.org/0000-0002-7783-9934

REFERENCES

1. Asher R. Histiocytic medullary reticulosis: a case without lymphadenopathy. Lancet. 1946;1(6401):650.
2. Bodley Scott R, Robb-Smith AHT. Histiocytic medullary reticulosis. Lancet. 1939;234(6047):194-198.
3. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;173(136):519-525.
4. Roder JC, Haliotis T, Klein M, et al. A new immunodeficiency disorder in humans involving NK cells. Nature. 1980;284(5756):553-555.
5. Rubin CM, Burke BA, McKenna RW, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer. 1985;56(3):524-530.
6. Perez N, Virelizier JL, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr. 1984;104(4):569-573.
7. Arico M, Nespoli L, Maccario R, et al. Natural cytotoxicity impairment in familial haemophagocytic lymphohistiocytosis. Arch Dis Child. 1988;63(3):292-296.
8. Elfe R, Janka GE, Belohradsky BH, Holtmann H. Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol. 1989;6(3):265-272.
9. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918-2922.
10. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3):221-230.
11. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL study group of the histiocytic society. Semin Oncol. 1991;18(1):29-33.
12. Silverman ED, Miller JJ 3rd, Bernstein B, Shafai T. Consumption agglutopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr. 1983;103(6):872-876.
13. Esumi N, Ikushima S, Todo S, Imashuku S. Hyperferritinemia in malignant histiocytosis and virus-associated hemophagocytic syndrome. N Engl J Med. 1987;316(6):346-347.
14. Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood. 1995;86(12):4706-4707.
15. Henter J-I, Horne AnnaCarin, Aroc M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
16. Barbosa MDFS, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 1996;382(6588):262-265.
17. Baert K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol. 1995;154(11):6122-6131.
18. Targan SR, Oseas R, The, "lazy" NK cells of Chediak-Higashi syndrome. J Immunol. 1983;130(6):2671-2674.
19. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265(5171):528-530.
20. Peters PJ, Borst J, Oorschot V, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991;173(5):1099-1109.
21. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20(2):129-135.
22. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA. 1998;95(23):13765-13770.
23. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395(6701):462-469.
24. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-1959.
25. Ménasché G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with hemophagocytic syndrome. Nat Genet. 2000;25(2):173-176.
26. Feldmann J, Callebaut I, Raposo G, et al. Munc-13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115(4):461-473.
28. zur Stadt U, Schmidt S, Kaspar B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type 4 to chromosome 6q24 and identification of mutations in syntaxis 11. Hum Mol Genet. 2005;14(6):827-834.

29. Côte M, Ménager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and improves cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119(12):3765-3773.

30. zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85(4):482-492.

31. Meeths M, Entesarian M, Al-Herz W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis (FHL) type 5 patients with mutations in STXBP2. Blood. 2010;116(15):2635-2643.

32. Pagel J, Beutel K, Lehmberg K, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood. 2012;119(25):6016-6024.

33. Bryceson YT, Rudd E, Zheng C, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood. 2007;110(6):1906-1915.

34. Sepulveda FE, Debeurme F, Ménasché G, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB2B7A, and STX11. Blood. 2013;121(4):595-603.

35. Horne A, Ramme KG, Rudd E, et al. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol. 2008;143(1):75-83.

36. Sieni E, Cetica V, Santoro A, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet. 2011;48(5):343-352.

37. Casanova JL, Abel L. Inborn errors of immunity to infection: the expected genetic disorders. N Engl J Med. 2005;352(2):197-201.

38. Meeths M, Horne A, Sabel M, Bryceson YT, Henter JI. Incidence, genetic underpinnings and clinical presentation of primary hemophagocytic lymphohistiocytosis type 3 familial hemophagocytic lymphohistiocytosis. Br J Haematol. 2013;121(4):595-603.

39. Rubin TS, Zhang K, Gifford C, Lane A, Blessing JJ, Marsh RA. Perforin and CD107a testing are superior to NK cell function testing for screening patients for genetic HLH. Blood. 2012;120(22):2993-2999.

40. Marshall MR, Pattu V, Halimani M, et al. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J Cell Biol. 2015;210(1):135-151.

41. Wood SM, Meeths M, Chiang SCC, et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood. 2009;114(19):4117-4127.

42. Ménager MM, Ménasché G, Romao M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol. 2007;8(3):257-267.

43. Shirakawa R, Higashi T, Tabuchi A, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem. 2004;279(11):10730-10737.

44. Elstak ED, Neeft M, Nehme NT, et al. The munc13-4-rab27 complex is specifically required for tethering secretory lysosomes at the plasma membrane. Blood. 2011;118(6):1570-1578.

45. Ma C, Li W, Xu Y, Rizo J. Munc13 mediates the transition from the closed syntaxin-Munc18 complex to the SNARE complex. Nat Struct Mol Biol. 2011;18(5):542-549.

46. Koch H, Hofmann K, Brose N. Definition of Munc13-homology domains and characterization of a novel ubiquitously expressed Munc13 isoform. Biochem J. 2000;349(Pt 1):247-253.

47. Gil-Krzewska A, Saeed MB, Oszmiana A, et al. An actin cytoskeleton barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome. J Allergy Clin Immunol. 2018;142(3):914-927.e6.

48. Kalinichenko A, Perinetti Casoni G, Dupré L, et al. RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis. Blood. 2021;137(15):2033-2045.

49. Matti U, Pattu V, Halimani M, et al. Synaptobrevin2 is the v-SNARE required for cytotoxic T-lymocyte granule fusion. Nat Commun. 2013;4:1439.

50. Chitirala P, Ravichandran K, Galgano D, et al. Cytotoxic granule exocytosis from human cytotoxic T lymphocytes is mediated by VAMP7. Front Immunol. 2019;10:1855.

51. Loo LS, Hwang LA, Ong YM, Tay HS, Wang CC, Hong W. A role for endobrevin/VAMP8 in CTL lytic granule exocytosis. Eur J Immunol. 2009;39(12):3520-3528.
66. Schmid JP, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117(5):1522-1529.

67. Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol. 2015;39:115-123.

68. Listen P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379(6653):349-353.

69. Canna SW, de Jesus AA, Gouni S, et al. An activating NLR4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140-1146.

70. Lam MT, Coppola S, Krumbach OHF, et al. A novel disorder involving dysshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med. 2019;216(12):2770-2779.

71. Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53-62.

72. Tangye SG, Latour S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood. 2020;135(9):644-655.

73. Moshous D, Martin E, Carpentier W, et al. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J Allergy Clin Immunol. 2013;131(6):1594-1603.

74. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-743.

75. Bode SF, Ammann S, Al-Herz W, et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015;100(7):978-988.

76. Tesi B, Sieni E, Neves C, et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-gamma receptor deficiency. J Allergy Clin Immunol. 2015;135(6):1638-1641.

77. Faitelson Y, Bates A, Shroff M, Grunebaum E, Roifman Chaim M, Naqvi A. A mutation in the STAT1 DNA-binding domain associated with hemophagocytic lymphohistiocytosis. LymphoSign J. 2014;1(2):87-95.

78. Staines-Boone AT, Deswarte C, Venegas Montoya E, et al. Multifocal recurrent osteomyelitis and hemophagocytic lymphohistiocytosis in a boy with partial dominant IFN-gammaR1 deficiency: case report and review of the literature. Front Pediatr. 2017;5:75.

79. Althonaian N, Alsultan A, Morava E, Alfadhel M. Secondary hemophagocytic syndrome associated with COG6 gene defect: report and review. JIMD Rep. 2018;42:105-111.

80. Janka GE, Lehmbarg K. Hemophagocytic syndromes--an update. Blood Rev. 2014;28(4):135-142.

81. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268.

82. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.

83. Burn TN, Weaver L, Rood JE, et al. Genetic deficiency of interferon-gamma reveals interferon-gamma-independent manifestations of murine hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):335-347.

84. van Dommele SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-Esposti MA. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity. 2006;25(5):835-848.

85. Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184(1):149-168.e17.

86. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264-2277.

87. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666-1675.

88. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint BG. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60-71.

89. Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1(19):1533-1536.

How to cite this article: Meeths M, Bryceson YT. Genetics and pathophysiology of haemophagocytic lymphohistiocytosis. Acta Paediatr. 2021;110:2903–2911. https://doi.org/10.1111/apa.16013